港股異動 | 漲勢如虹!五菱汽車尾盤漲超32%
uSMART盈立智投12月28日消息,週一港股,"人民的"五菱汽車漲勢如虹!尾盤漲超32%,最高觸及3港元(截至15:36分)。
近期五菱旗下一款新能源車"五菱宏光MINIEV"橫空出世,售價僅2.88-3.88萬元人民幣,上市只兩月便打敗特斯拉,一舉成爲新能源汽車銷冠。
根據乘聯會數據顯示,9月MINIEV銷量達14,495輛,就把特斯拉推下長期霸佔月銷量王座;10月份對比更慘烈,MINIEV銷量進一步升至20,631輛,幾乎達到特斯拉2倍;11月MINIEV銷量進一步升至33,094輛,單日銷量最高突破2,000輛。累計來看,這款於今年7月上市的車型,已經獲得了10.04萬輛的總銷量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.